ESTRO 2025 - Abstract Book

S2328

Interdisciplinary – Health economics & health services research

ESTRO 2025

References: 1. Amjad, R., et al (2024). Hypofractionated Radiotherapy in Gynecologic Malignancies; A Peek into the Upcoming Evidence. Journal of Clinical Oncology, 42(5) 2. Sher, D. J. (2010). Cost-effectiveness in radiation oncology. Expert Review of Pharmacoeconomics & Outcomes Research, 10(2), 123-129. 3. Toscano, F., et al. (2021). The role of cost-effectiveness analysis in patient-centered cancer care in the era of precision medicine. Cancers, 13(17), 4272. 4. Varmaghani, M., et al. (2023). The cost effectiveness of IMRT and 3D CRT in the treatment of head and neck cancers. Radiation Oncology, 18, 138. 5. Sher, D. J., & Punglia, R. S. (2021). Cost-effectiveness analysis of radiotherapy techniques for whole breast irradiation. PLOS ONE, 16(3)

3791

Digital Poster Organisational Impact of 5 Fractions Radiotherapy in Adjuvant Breast Cancer Treatment in France Gabrielė Bielinytė 1,2 , Valentine Grumberg 3 , Isabelle Borget 4 , Sophie Guillerme 5 , Laure Grelier 6 , Laetitia Padovani 6 , Candice Milewski 1 , Guillaume Ausac 1 , Guillaume Louvel 1 , Pierre Maroun 7 , Sofia Rivera 1 1 Radiation Oncology, Institut Gustave Roussy, Paris, France. 2 Radiation Oncology, National Cancer Institute, Vilnius, Lithuania. 3 Santé Publique, Bristol Myers Squibb & Université Paris Saclay, Paris, France. 4 Biostatistics and Epidemiology, Institut Gustave Roussy, Paris, France. 5 Radation Oncology, Assistance hôpitaux publique de Paris, Paris, France. 6 Radiation Oncology, Assistance publique hôpitaux de Marseille, Marseille, France. 7 Radiation Oncology, Institut de radiothérapie du Sud de l'Oise, Creil, France Purpose/Objective: In 2020, the French National Authority for Health (Haute Autorité de Santé) introduced a methodological guide titled 'Organisational Impact (OI) Cartography,' aimed at defining and structuring the assessment of health technologies' OI (1). The implementation of a one-week whole breast radiotherapy regimen based on the results of the Fast Forward trial (2) was the primary reason for conducting our organisational impact study, as it offered a unique opportunity to assess not only potential cost savings and improved patient accessibility, but also its broader effects on organisational dynamics, environmental factors, and the healthcare professionals involved. Material/Methods: To assess the organizational impacts of a 5-fractions whole breast irradiation regimen, we conducted semi structured interviews with healthcare professionals (HCPs) and patients, alongside a comprehensive literature review. Interviews were conducted at cancer centers, university hospitals, private clinics, and the Cancer Center Federation (UNICANCER) in France. Participants were asked about the impacts of this radiotherapy regimen, classified into three categories: care process (six criteria), required capacities and skills (six criteria), and societal impact (four criteria). We recorded the significance (minor, moderate, or major) and timing of identified impacts, defining an organizational impact as one reported by at least 75% of participants for a given criterion. In the absence of established guidelines for assigning weight, we set a minimum threshold of 3 points to indicate a strong impact. Results: Interviews were conducted with 17 healthcare professionals (HCPs) and 5 patients (Figure 1). Impacts were noted by >=75% HCPs for 5 of 16 criteria, whereas we found reported impacts for 10 of these criteria mentioned in the literature. (3-7) Three criteria (process rhythm or duration, scheduling and planning capabilities for health services, and environmental footprint) had consensus among HCPs and a high impact; two criteria (skills and expertise, inequality) showed consensus but a moderate impact; seven criteria (funding, working/living conditions, chronology, time before initiation, material, health and safety, quantity of human resource involved) had a high impact but no